Reddy, N., Rezvani, K., Barrett, A.J., et al. (2011) Strategies to Prevent EBV Reactivation and Posttransplant Lymphoproliferative Disorders (PTLD) after Allogeneic Stem Cell Transplantation in High-Risk Patients. Biol Blood Marrow Transplant, 17, 591-597. https://doi.org/10.1016/j.bbmt.2010.08.007

has been cited by the following article:

• TITLE: EBV-Associated Post-Transplantation B-Cell Lymphoproliferative Disorder in Patient after Allogenic Stem Cell Transplantation

  AUTHORS: Li Tang, Yu Li

  KEYWORDS: Post-Transplantation Lymphoproliferative Disorder, Allogeneic Hematopoietic Stem Cell Transplantation, Epstein-Barr Virus

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.7 No.5, May 17, 2019

  ABSTRACT: Epstein-Barr virus (EBV)-associated B-cell post-transplantation lymphoproliferative disorder (PTLD) is a severe complication following solid-organ transplantation (SOT) and allogeneic hematopoietic stem cell transplantation (HSCT). We present a case of a 15-year-old male developing a monomorphic B-cell PTLD after receiving an allogenic stem cell transplant for acute acute myeloid leukemia. A diagnostic lymph node biopsy revealed monomorphic type, B cell phenotype, associated with Epstein-Barr virus, consistent with post-transplant lymphoproliferative disorder (PTLD). The morbidity and mortality of PTLD are high, and there is no standard protocol for treatment of PTLD. To prevent the occurrence of PTLD and early intervention are important for the prognosis of patients.